OBJECTIVES: Intracerebral hemorrhage (ICH) is a highly lethal disease of the elderly. Use of statins is increasingly widespread among the elderly, and therefore common in patients who develop ICH. Accumulating data suggests that statins have neuroprotective effects, but their association with ICH outcome has been inconsistent. We therefore performed a meta-analysis of all available evidence, including unpublished data from our own institution, to determine whether statin exposure is protective for patients who develop ICH. METHODS: In our prospectively ascertained cohort, we compared 90-day functional outcome in 238 pre-ICH statin cases and 461 statin-free ICH cases. We then meta-analyzed results from our cohort along with previously published studies using a random effects model, for a total of 698 ICH statin cases and 1,823 non-statin-exposed subjects. RESULTS: Data from our center demonstrated an association between statin use before ICH and increased probability of favorable outcome (odds ratio [OR] = 2.08, 95% confidence interval [CI] 1.37-3.17) and reduced mortality (OR = 0.47, 95% CI 0.32-0.70) at 90 days. No compound-specific statin effect was identified. Meta-analysis of all published evidence confirmed the effect of statin use on good outcome (OR = 1.91, 95% CI 1.38-2.65) and mortality (OR = 0.55, 95% CI 0.42-0.72) after ICH. CONCLUSION: Antecedent use of statins prior to ICH is associated with favorable outcome and reduced mortality after ICH. This phenomenon appears to be a class effect of statins. Further studies are required to clarify the biological mechanisms underlying these observations.
OBJECTIVES:Intracerebral hemorrhage (ICH) is a highly lethal disease of the elderly. Use of statins is increasingly widespread among the elderly, and therefore common in patients who develop ICH. Accumulating data suggests that statins have neuroprotective effects, but their association with ICH outcome has been inconsistent. We therefore performed a meta-analysis of all available evidence, including unpublished data from our own institution, to determine whether statin exposure is protective for patients who develop ICH. METHODS: In our prospectively ascertained cohort, we compared 90-day functional outcome in 238 pre-ICH statin cases and 461 statin-free ICH cases. We then meta-analyzed results from our cohort along with previously published studies using a random effects model, for a total of 698 ICH statin cases and 1,823 non-statin-exposed subjects. RESULTS: Data from our center demonstrated an association between statin use before ICH and increased probability of favorable outcome (odds ratio [OR] = 2.08, 95% confidence interval [CI] 1.37-3.17) and reduced mortality (OR = 0.47, 95% CI 0.32-0.70) at 90 days. No compound-specific statin effect was identified. Meta-analysis of all published evidence confirmed the effect of statin use on good outcome (OR = 1.91, 95% CI 1.38-2.65) and mortality (OR = 0.55, 95% CI 0.42-0.72) after ICH. CONCLUSION: Antecedent use of statins prior to ICH is associated with favorable outcome and reduced mortality after ICH. This phenomenon appears to be a class effect of statins. Further studies are required to clarify the biological mechanisms underlying these observations.
Authors: K J Becker; A B Baxter; W A Cohen; H M Bybee; D L Tirschwell; D W Newell; H R Winn; W T Longstreth Journal: Neurology Date: 2001-03-27 Impact factor: 9.910
Authors: Jieli Chen; Zheng Gang Zhang; Yi Li; Ying Wang; Lei Wang; Hao Jiang; Chenling Zhang; Mei Lu; Mark Katakowski; Carolyn S Feldkamp; Michael Chopp Journal: Ann Neurol Date: 2003-06 Impact factor: 10.422
Authors: M Gomis; A Ois; A Rodríguez-Campello; E Cuadrado-Godia; J Jiménez-Conde; I Subirana; A Dávalos; J Roquer Journal: Eur J Neurol Date: 2009-11-12 Impact factor: 6.089
Authors: Laura C Gioia; Mahesh Kate; Rebecca McCourt; Bronwen Gould; Shelagh B Coutts; Dariush Dowlatshahi; Negar Asdaghi; Thomas Jeerakathil; Michael D Hill; Andrew M Demchuk; Brian Buck; Derek Emery; Ashfaq Shuaib; Kenneth Butcher Journal: J Cereb Blood Flow Metab Date: 2015-03-11 Impact factor: 6.200
Authors: Rajeev K Garg; Jawad Khan; Robert J Dawe; James Conners; Sayona John; Shyam Prabhakaran; Mehmet Kocak; Sudeep Bhabad; Sean L Simpson; Bichun Ouyang; Miral Jhaveri; Thomas P Bleck Journal: Neurocrit Care Date: 2020-10 Impact factor: 3.210
Authors: Guido J Falcone; H Bart Brouwers; Alessandro Biffi; Christopher D Anderson; Thomas W K Battey; Alison M Ayres; Anastasia Vashkevich; Kristin M Schwab; Natalia S Rost; Joshua N Goldstein; Anand Viswanathan; Steven M Greenberg; Jonathan Rosand Journal: Neurocrit Care Date: 2014-10 Impact factor: 3.210
Authors: Alessandro Biffi; Abbas Rattani; Christopher D Anderson; Alison M Ayres; Edip M Gurol; Steven M Greenberg; Jonathan Rosand; Anand Viswanathan Journal: Brain Date: 2016-08-06 Impact factor: 13.501
Authors: Ching-Jen Chen; Dale Ding; Natasha Ironside; Thomas J Buell; Lori J Elder; Amy Warren; Amy P Adams; Sarah J Ratcliffe; Robert F James; Neeraj S Naval; Bradford B Worrall; Karen C Johnston; Andrew M Southerland Journal: Neurology Date: 2019-11-11 Impact factor: 9.910
Authors: Kathryn N Kearns; Natasha Ironside; Min S Park; Bradford B Worrall; Andrew M Southerland; Ching-Jen Chen; Dale Ding Journal: Neurocrit Care Date: 2021-08-02 Impact factor: 3.210